Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01736696 · ClinicalTrials.gov registry record · Phase 1
Multiple Dose Escalation Study In Medically Stable Subjects With Psoriasis
A Phase 1 study of Psoriasis and Immunomodulation, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 59
- Enrollment target
- 1
- Study location
NCT01736696 is a Phase 1 study of Psoriasis and Immunomodulation that has completed, run by Pfizer. The registered enrollment target is 59 participants, below the 488-participant average among 125 other Psoriasis trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01736696, a Phase 1 study of Psoriasis and Immunomodulation, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 59 participants
- Enrollment target
- 1
- Study location
Study Summary
This study was conducted in subjects with psoriasis to evaluate drug activity in this patient population by analysis of changes in psoriatic lesion biopsy characteristics. This subject population was selected to evaluate potentially relevant biological activity of CP-690,550 as well as assessing safety and pharmacokinetics.
Conditions Studied
Interventions
- DRUG tofacitinib
Study Locations (1)
Arkansas
- Pfizer Investigational Site - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2002-11 |
| Est. Completion | 2004-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01736696
The ClinicalTrials.gov registry entry for NCT01736696 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 59 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 488-participant average among 125 other Psoriasis trials with a reported enrollment target (88% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Psoriasis appearing as the primary indexed condition, and to 1 intervention - of which tofacitinib is the first listed.
NCT01736696 reports 1 study location spanning 1 distinct geographic area - top geographies include Arkansas.
Frequently Asked Questions
What is clinical trial NCT01736696 about?
NCT01736696 is a clinical study titled "Multiple Dose Escalation Study In Medically Stable Subjects With Psoriasis". This study was conducted in subjects with psoriasis to evaluate drug activity in this patient population by analysis of changes in psoriatic lesion biopsy characteristics. This subject population was selected to evaluate potentially relevant biological activity of CP-690,550 as well as assessing saf...
What is the current status of trial NCT01736696?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 59 participants. The study started on 2002-11. Estimated completion is 2004-04.
What conditions does trial NCT01736696 study?
This clinical trial studies the following conditions: Psoriasis, Immunomodulation.
What interventions are being tested in trial NCT01736696?
The interventions under investigation include: tofacitinib (DRUG).
Who is sponsoring clinical trial NCT01736696?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01736696 being conducted?
This trial has 1 study location across Arkansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
RECRUITING · Phase 1
-
Evaluate the Safety and Pharmacokinetics/Pharmacodynamics of HS-20118
RECRUITING · Phase 1
-
Study of SFA002 in Patients with Mild to Moderate Psoriasis Plaques
RECRUITING · Phase 1
-
Maximal Usage Pharmacokinetics and Safety Study of ARQ-154 Foam 0.3% in Pediatric Participants With Scalp and Body Psoriasis
RECRUITING · Phase 1
-
Pharmacokinetic Study to Evaluate the Effect of a Single Dose of Guselkumab (CNTO 1959) on CYP 450 Enzyme Activities After Subcutaneous Administration in Participants With Psoriasis
COMPLETED · Phase 1
-
Study Evaluating The Safety And Tolerability Of ILV-094 In Subjects With Psoriasis
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.